Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 11/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785601 | 0.87 | MEN1 (0.46) | MAOAMAOBACHEBCHE | |
| SCHEMBL785602 | 0.87 | MEN1 (0.46) | MAOAMAOBACHEBCHE | |
| SCHEMBL784661 | 0.86 | ACHE (0.57) | MAOAMAOBACHEDRD3BCHE | |
| SCHEMBL784272 | 0.83 | ALDH1A1 (0.45) | MAOAMAOBACHEDRD3ALDH1A1 | |
| SCHEMBL785600 | 0.83 | PDE4A (0.42) | MAOAMAOBDRD3ALDH1A1HTT | |
| SCHEMBL784523 | 0.83 | PDE4A (0.42) | MAOAMAOBDRD3ALDH1A1HTT | |
| SCHEMBL484852 | 0.81 | ACHE (0.54) | MAOAMAOBACHEDRD3ALDH1A1 | |
| SCHEMBL784694 | 0.81 | CYP1A2 (0.41) | MAOAMAOBACHEDRD3ALDH1A1 | |
| SCHEMBL785774 | 0.81 | CYP1A2 (0.41) | MAOAMAOBACHEDRD3ALDH1A1 | |
| SCHEMBL878683 | 0.81 | MAOA (0.42) | MAOAMAOBACHEDRD3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | MAOA 726/4885MAOB 261/4885ACHE 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.